Bristol-Myers Squibb Company (ETR: BRM)
Germany
· Delayed Price · Currency is EUR
56.46
+1.22 (2.21%)
Nov 22, 2024, 5:35 PM CET
BRM Revenue
Bristol-Myers Squibb Company had revenue of $11.89B USD in the quarter ending September 30, 2024, with 8.44% growth. This brings the company's revenue in the last twelve months to $47.44B, up 5.56% year-over-year. In the year 2023, Bristol-Myers Squibb Company had annual revenue of $45.01B, down -2.50%.
Revenue (ttm)
$47.44B
Revenue Growth
+5.56%
P/S Ratio
n/a
Revenue / Employee
$1.39M
Employees
34,100
Market Cap
112.59B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBristol-Myers Squibb Company News
- 7 days ago - Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue - Benzinga
- 7 days ago - Bristol Myers gets positive EMA opinion for repotrectinib - Seeking Alpha
- 7 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - Wallstreet:Online
- 7 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors - Wallstreet:Online
- 10 days ago - AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - Benzinga
- 10 days ago - This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
- 10 days ago - Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock - Benzinga
- 10 days ago - AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say - MarketWatch